Pharma Can Reset Reputation In Pandemic, Says Novartis CEO

'Once-In-A-Generation Opportunity'

29 Apr 2020

Vas Narasimhan hopes that donations and the "unprecedented collaborations" between drugmakers trying to overcome the COVID-19 pandemic is leading to a shift in the perception of the value of the sector to society.

Virtual_Screen_Smile — Pharma's Approval Ratings Are On The Up • Source: Shutterstock

The pharmaceutical industry's concerted efforts to fight COVID-19 might represent "a remarkable, perhaps once-in-a-generation opportunity to reset our reputation in the broader public mind," claims Novartis AG CEO Vas Narasimhan.

Speaking after the Swiss major unveiled a strong set of financials for the 2020 first quarter on 28 April, Narasimhan said, "We’re in a moment in time where our industry, combined with the work of academia and the broader ecosystem, has stepped up to make unprecedented collaborations

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Industry Leaders Grapple With Trump’s MFN Pricing Plan

14 May 2025

• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.